Browsing: CDK46i

Diagnosis

107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)

By NewsCancerMay 17, 20260

BackgroundAt SERENA-6 interim analysis, switching to camizestrant, with continued CDK4/6 inhibitor (CDK4/6 i), at ESR1 mutationemergence during first-line aromatase inhibitor…

Diagnosis

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

By NewsCancerMay 2, 20260

BackgroundEndocrine therapy (ET) plus CDK4/6 inhibitor (CDK4/6i) is the standard-of-care (SOC) in first-line estrogen receptor–positive (ER+/HER2-negative (HER2–) advanced breast cancer;…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?

Lauren Laverne diagnosed with blood disorder smouldering myeloma

Breast cancer detection and classification via a robust deep learning approach

Browsing: CDK46i

TIP137 ADELA: A Double-blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?

Lauren Laverne diagnosed with blood disorder smouldering myeloma

Breast cancer detection and classification via a robust deep learning approach

Sequencing Treatment after EV-Pembro in Urothelial Carcinoma

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?

Lauren Laverne diagnosed with blood disorder smouldering myeloma

Breast cancer detection and classification via a robust deep learning approach

Sequencing Treatment after EV-Pembro in Urothelial Carcinoma

Latest Post

How Do Updated NCCN Guidelines and ctDNA Data Reshape MIBC Treatment?

Lauren Laverne diagnosed with blood disorder smouldering myeloma

Breast cancer detection and classification via a robust deep learning approach

Subscribe to Updates

What's Hot

Browsing: CDK46i